Company Data

AbbVie Total Revenue (Immunology) - Global

(in million U.S. dollars)

Description

AbbVie Inc. is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care.

Immunology Portfolio: AbbVie maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology. 

  • HUMIRA®
  • SKYRIZI®
  • RINVOQ®

Revenue (2024):

  • Worldwide sales (net revenue) were $56.3 billion in 2024, an increase of 3.71% compared with 2023 ($54.3 billion)
  • Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis
  • Skyrizi ($11.718 billion) and Rinvoq ($5.971 billion) performed exceptionally well, generating more than $17.6 billion in combined sales in 2024 

AbbVie forecasts 2025

AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2025 of $12.12 to $12.32. The company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred during 2025, as both cannot be reliably forecasted.

Long-Term Outlook

AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes 2024 as the base year in the compound annual growth rate calculation.

AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues. The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion, an increase of approximately $4 billion compared to previous guidance for combined revenues of more than $27 billion in 2027. This guidance assumes Skyrizi revenues of more than $20 billion and Rinvoq revenues of more than $11 billion in 2027.

AbbVie is also updating its outlook for aesthetics revenues. The company now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029. This guidance assumes 2025 as the base year in the compound annual growth rate calculation.

  • Last Updated Date : 25 Feb 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : AbbVie Inc., (ANNUAL REPORT FORM 10-K)
  • Competitors : Johnson & Johnson, Sanofi, Novartis, AstraZeneca, Amgen, Roche
Johnson & Johnson Total Revenue (Immunology) - Global

(in million U.S. dollars)

Description

Johnson & Johnson and its subsidiaries (the Company) is engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Company is organized into two business segments: Innovative Medicine and MedTech.

Immunology Portfolio (Innovative Medicine): Johnson & Johnson maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology

  • STELARA ®
  • TREMFYA ®
  • SIMPONI/SIMPONI ARIA ®
  • REMICADE

Revenue (2024):

  • Innovative Medicine segment sales in 2024 were $57.0 billion, an increase of 4.0% from 2023 ($54.75 billion), which included operational growth of 5.7% and a negative currency impact of 1.7%.
  • Full-Year Global Net Revenues from the Immunology Portfolio Were $17.828 Billion in 2024, Decrease of 1.2 Percent as compared to 2023 ($18.052 Billion).
  • Sales of STELARA worldwide were $10.361 billion in fiscal 2024.
  • Decline of STELARA (ustekinumab) sales was driven by share loss primarily due to European biosimilar entrants.
  • Lower sales of REMICADE (infliximab) was due to continued biosimilar competition.
  • The growth of TREMFYA(guselkumab) was due to market growth and share gains partially offset by unfavorable patient mix and inventory dynamics. 

2025 Phasing Considerations

  • Expect more pronounced impact from newly launched products as the year progresses. TREMFYA in inflammatory bowel disease: already approved in ulcerative colitis. Crohn's Disease approval expected in 2025. TREMFYA is expected to be more than a $10 billion product.
  • STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy.
  • Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year

  • Last Updated Date : 04 Mar 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Johnson & Johnson (ANNUAL REPORT FORM 10-K), Earnings Presentation, J.P. Morgan Healthcare Conference
  • Competitors : AbbVie, Sanofi, Novartis, AstraZeneca, Amgen, Roche
Eli Lilly and Company Total Revenue (Immunology) - Global

(in million U.S. dollars)

Description

Eli Lilly and Company (referred to as the company, Lilly) a drug manufacturing company discovers, develops, manufactures, and markets products in a single business segment—human pharmaceutical products. Eli Lilly focuses on four core therapeutic areas— Cardiometabolic Health products, Immunology, Neuroscience and Oncology

Immunology Portfolio: Eli Lilly and Company maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology.

  • Ebglyss®
  • Olumiant® - worldwide license and collaboration agreement with Incyte Corporation
  • Omvoh®
  • Taltz 

Revenue (2024):

  • Worldwide sales were $45.0 billion in 2024, an increase of 32% compared with 2023 ($34.12 billion)
  • Full-Year Global Net Revenues from the Immunology Portfolio were $4.393 billion in 2024, an increase of 15.67 Percent as compared to 2023 ($3.797 billion)
  • Sales of Taltz® worldwide were $3.26 billion in fiscal 2024 an increase of 18 Percent as compared to 2023 ($2.76 billion) driven by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand.

2025 revenue guidance:

  • The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue
  • Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca®, Ebglyss™, Omvoh® (Immunology Portfolio) and Kisunla™; approvals of new indications for existing Lilly medicines
  • Pipeline progress included the approval of Omvoh in the U.S. for moderately to severely active Crohn's disease

  • Last Updated Date : 06 Feb 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Eli Lilly and Company (ANNUAL REPORT FORM 10-K), Earnings Presentation
  • Competitors : AbbVie, Johnson & Johnson, Sanofi, Novartis, AstraZeneca, Amgen, Roche
Roche Total Revenue (Immunology) - Global

(in million Swiss Franc)

Description

Roche is one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. A global pioneer in pharmaceuticals and diagnostics. #1 in Neurology, a leader in Ophthalmology and Oncology/Hematology. Roche focuses on five core therapeutic areas (Pharmaceuticals Division) - Oncology/Haematology, Immunology, Neurology, Ophthalmology and Cardiovascular/Renal/Metabolism. 

Immunology Portfolio (Pharmaceuticals Division):

  • Actemra/RoActemra
  • Xolair
  • Pulmozyme
  • CellCept
  • MabThera/Rituxan 

Revenue (2024):

  • Worldwide sales in the Pharmaceuticals Division were CHF 46.2 billion (2023: CHF 44.3 billion), an increase of 8% at CER
  • Full-Year Global Net Revenues from the Immunology Portfolio were CHF 6.329 billion (2023: CHF 6.242 billion)
  • Actemra/RoActemra sales increased by 5% CHF 2.645 billion (2023: CHF 2.630 billion), resulting from increased demand from patients with rheumatoid arthritis. The first biosimilar versions of Actemra/RoActemra came to market in the EU in the fourth quarter of 2023, which drove the sales decline in Europe. In the US, the first biosimilar versions entered the market in the second quarter of 2024
  • Xolair sales in the US were 16% higher driven by growth in the chronic spontaneous urticaria indication and the launch of the medicine in the food allergy indication. Sales of Xolair in the US in 2024 were CHF 2.470 billion (2023: CHF 2.176 billion). First biosimilar versions could come to market in the US in 2026.

  • Last Updated Date : 28 Jan 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : ROCHE (ANNUAL REPORT, FINANCE REPORT), Investor Presentation
  • Competitors : AbbVie, Johnson & Johnson, Sanofi, Novartis, AstraZeneca, Amgen, Eli Lilly and Company
Novartis Total Revenue (Immunology) - Global

(in million U.S. dollars)

Description

Novartis is an innovative medicines company, engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of innovative pharmaceutical medicines. Novartis focuses on four core therapeutic areas with strong growth potential and high unmet patient needs—cardiovascular, renal and metabolic; immunology; neuroscience; and oncology.

Immunology Portfolio (Innovative Medicine): Novartis maintains an extensive immunology portfolio across rheumatology, dermatology and gastroenterology

  • Cosentyx® (Key marketed product)
  • Xolair® - Novartis co-promotes Xolair with Genentech in the US and shares a portion of revenue as operating income but does not record any US sales
  • Ilaris®
  • Myfortic®
  • Neoral®/Sandimmune®
  • Simulect®
  • Zortress®/Certican®

Revenue (2024):

  • In 2024, Novartis achieved net sales from continuing operations of USD 50.3 billion.
  • Net sales in the immunology therapeutic area reached USD 9.3 billion (+19%, +21% cc) as compared to 2023 ($7.8 Billion) with sales growth mainly driven by Cosentyx.
  • Cosentyx (USD 6.1 billion); Xolair (USD 1.6 billion); Ilaris (USD 1.5 billion)

2025 Growth Plans:

  • Net sales expected to grow high single-digit
  • Core operating income expected to grow low double-digit
  • Cosentyx: Expecting 8bn+ assuming US LoE in 2029
  • 30+ potential high-value NME assets in pipeline
  • Immunology: Expecting 6 Phase III readouts and >10 Phase II readouts1 in the next 5 years

  • Last Updated Date : 30 Jan 2025
  • Study Period : 2018-2024
  • Category : Company Data
  • Sources : Novartis (ANNUAL REPORT FORM 10-K), Earnings Presentation, Investors Presentation
  • Competitors : AbbVie, Johnson & Johnson Sanofi, AstraZeneca, Amgen, Roche

Have questions about how our healthcare intelligence solutions can empower your organization?

up